Sign up USA
Proactive Investors - Run By Investors For Investors

Exelixis shares soar on news FDA grants priority review to its kidney cancer drug

Kidney cancer is one of the top 10 most common forms of cancer in the U.S., the company said
dialysis
If the biotech wins FDA approval, it will be able to make changes to the product label, including modifications to the indication.

Biotech Exelixis Inc. (NASDAQ:EXEL) saw its shares surge in premarket trade on Monday after the U.S. Food and Drug Administration granted priority review status for its supplemental New Drug Application (sNDA) for the treatment for advanced renal cell carcinoma (RCC).

In a statement, the company said the sNDA is based on results from a mid-stage trial of Cabometyx, and is aimed at patients with previously untreated advanced RCC.

READ: Exelixis to start new combo cancer trials with Bristol-Myers and Roche

If the biotech wins FDA approval, it will be able to make changes to the product label, including modifications to the indication.

Cabometyx was given the green light by the FDA in April of 2016 for the treatment of patients with advanced RCC who have received prior anti-angioegenic therapy, or drugs that stop tumors from growing their own blood vessels.

Kidney cancer is one of the top 10 most common forms of cancer in the U.S., the company said.

In premarket trade, its shares surged 23.63% at US$30.61.

View full EXEL profile View Profile

Exelixis Timeline

Related Articles

profit meter
April 02 2018
Having secured US$6.9mln of new investment, the company is now primed for growth
1511808112_surgeon.jpg
January 08 2018
The device can now be sold to aid in heart treatment throughout the European Union
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use